Methotrexate Ebewe Pharma

Methotrexate, the active ingredient in Methotrexate Ebewe Pharma, is an antimetabolite presented as an injectable solution for intraarterial, intramuscular, and intravenous use. It treats rheumatoid arthritis, psoriasis, certain leukemias and other malignancies, and is used in gestational trophoblastic disease.

GNH USA supplies Methotrexate Ebewe Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is employed in several disease categories where rapid cell proliferation or immune activation is a key feature.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell turnover, improving plaque severity. - Acute lymphoblastic leukemia: interferes with malignant lymphoblast replication, contributing to remission. - Osteosarcoma: inhibits tumor growth as part of combination chemotherapy. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe, depending on dose and patient factors.

Common Side Effects: - Nausea and vomiting - Fatigue - Mucositis (mouth sores) - Elevated liver enzymes

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Severe hepatotoxicity or fibrosis - Pulmonary toxicity (interstitial pneumonitis)

Methotrexate requires careful monitoring and specific safety measures before and during therapy.

- Pregnancy: contraindicated; classified as Category X due to high teratogenic risk. - Renal function: assess baseline renal status; impaired function may increase toxicity. - Hepatic function: monitor liver enzymes regularly; avoid use in active liver disease. - Infection risk: watch for signs of infection as immunosuppression can be profound. - Concomitant folate: consider folic acid supplementation to mitigate mucosal and hematologic toxicity. - Store at ambient temperature: keep in original container, protect from light and moisture.

Methotrexate interacts with several drug classes, requiring avoidance or close monitoring.

Major Interactions (Avoid): - NSAIDs: increase risk of renal toxicity. - Proton pump inhibitors: may elevate methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: synergistic bone marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive immunosuppression. - Live vaccines: risk of infection; avoid during therapy. - Alcohol: may exacerbate hepatotoxicity.